AI Article Synopsis
Article Abstract
We identified all children enrolled in the Intergroup Rhabdomyosarcoma Study Group-IV with neurofibromatosis type I (NF1) and rhabdomyosarcoma. Among 1025 eligible patients, 5 (0.5 %) had NF1. Three children had relapses, two of whom died of progressive disease. Patients with NF1 and rhabdomyosarcoma should be treated with intensive contemporary therapy protocols.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpeds.2004.02.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Pediatr Blood Cancer
January 2025
Division of Pediatric Hematology-Oncology, Mayo Alix School of Medicine, Rochester, New York, USA.
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1.
View Article and Find Full Text PDFPrimary orbital and adnexal rhabdomyosarcoma: a study of 54 Asian Indian patients.
Orbit
October 2024
The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
Purpose: To describe the clinical presentation, management, and outcomes of orbital and adnexal rhabdomyosarcoma (RMS) in an Asian-Indian cohort and analyze the factors predictive of outcomes.
Methods: Retrospective interventional case series of 54 patients of histopathology-proven RMS.
Results: The mean age of presentation with RMS was 10 years (median, 7 years; range, <1-54 years).
Plasma-derived extracellular vesicles miR-335-5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma.
J Exp Clin Cancer Res
October 2024
Hematology/Oncology and Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Article Synopsis
- Researchers are exploring extracellular vesicle (EV)-carried miRNAs as potential biomarkers for assessing tumor aggressiveness and tailoring therapies, due to their stability and tissue specificity.
- A study identified nine miRNAs significantly upregulated in RMS patients, with miR-335-5p showing promise as a marker for distinguishing ARMS from ERMS, correlating with disease severity and patient survival outcomes.
Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.
Int J Clin Oncol
November 2024
Department of Pediatric Surgery, International University of Health and Welfare Hospital, Tokyo, Japan.
Background: Failure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m. However, this dose may increase the risk of adverse events, including infertility, in some patients.
View Article and Find Full Text PDFBackground: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS).
Patients And Methods: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!